Heated Debate Between China’s Ministries On Health Care Reform
This article was originally published in PharmAsia News
Executive Summary
China's Ministry of Health and Ministry of Human Resources and Social Security recently had a heated debate on the national basic medicine system at a seminar. MHRSS stressed its viewpoint that medical insurance organizations which cover the cost of drugs should wield 'group purchase' power to negotiate reasonable rates with drug suppliers, as well as work within the constraints of medical insurance payment structure to spur basic medicine usage by medical institutions. However, MOH strongly reiterated its stance that the government should identify basic medicine production locations for direct distribution, and mandate usage by medical institutions. Participants at the event observed that the two ministries are essentially fighting over the domination right of basic medicine. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.